STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.

STERIS plc announced a definitive agreement to acquire Xodus Medical, a specialty surgical products company, for $2.1 billion (net purchase price ~$1.8 billion after tax benefits). The acquisition is expected to close by December 31, 2026, and includes potential earnout consideration up to $150 million. Xodus Medical generated approximately $245 million in annual revenue for 2026 with $135 million in adjusted EBIT. STERIS expects the transaction to be accretive to top-line growth, margins, and adjusted earnings.

ResearchAndMarkets.com released a comprehensive market report on China's sterilization equipment industry covering chemical, physical, and ultraviolet sterilizers. The report provides revenue, volume, and pricing data from 2018-2033, competitive analysis of major players, and strategic insights for market entry and expansion in this growing sector.

STERIS reported strong Q1 fiscal 2027 results with adjusted EPS of $2.59 (up 10.7% YoY) beating estimates by 1.97%, driven by higher volume, pricing, and productivity across all segments. However, revenues of $1.49 billion missed consensus by 0.83%. The company reaffirmed its fiscal 2027 guidance for 7-8% revenue growth and $11.10-$11.30 adjusted EPS. Despite solid earnings, shares have underperformed the S&P 500 by 2.1% since the report.

STERIS plc announced it will host a conference call on August 6, 2026, at 9:00 a.m. ET to discuss its fiscal 2027 first quarter results. A press release with financial details will be issued after market close on August 5, 2026. The company is a leading global provider of infection prevention and healthcare products and services.

STERIS plc (NYSE:STE) announced a quarterly dividend of $0.63 per share, payable on June 26, 2026, to shareholders of record as of June 8, 2026. The company is a leading global provider of products and services supporting patient care with a focus on infection prevention.

STERIS plc announced a quarterly dividend of $0.63 per share, payable on March 19, 2026, to shareholders of record as of February 17, 2026. The company, a leading global provider of infection prevention products and services for healthcare and life sciences, continues its dividend distribution program.

CooperCompanies announced the appointment of Walt M Rosebrough, Jr., former CEO of STERIS, as an independent director effective January 3, 2026, following a cooperation agreement with activist investor Browning West. Rosebrough will join the Corporate Governance & Nominating Committee with consideration for Board Chair by end of 2026. The company also committed to appointing a new independent director with medical technology experience.

STERIS plc announced a quarterly dividend of $0.63 per share, payable on December 18, 2025, to shareholders of record as of November 18, 2025. The company is a global provider of healthcare and life science products focused on infection prevention.

The Dominican Republic celebrated National Free Zones Day, highlighting its strategic potential for global manufacturing and innovation. Key executives from international companies shared success stories, emphasizing the country's skilled workforce, strategic location, and business-friendly environment.

STERIS plc announced a quarterly dividend increase of $0.06 to $0.63 per share, marking its 20th consecutive year of dividend growth. The dividend will be payable on September 26, 2025, to shareholders of record as of September 4, 2025.

The global single-use surgical instruments market is projected to grow from $5.92 billion in 2025 to $7.80 billion by 2030, driven by demands for sterility, efficiency, and reduced infection risks in surgical procedures.